ClinicalTrials.Veeva

Menu
Z

Ziaderm Research | North Miami Beach, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Remibrutinib
JNJ-77242113
INF904
Dupilumab
PF-07264660
Lebrikizumab
LOU064
Ritlecitinib
etrasimod
PF-07275315

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 11 total trials

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents with Nonsegmental Vitiligo (Active and Stable) Tranquillo

Active, not recruiting
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in pa...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo 1
Drug: Placebo 2

The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deu...

Active, not recruiting
Plaque Psoriasis
Drug: Deucravacitinib Matching Placebo
Drug: JNJ-77242113 Matching Placebo

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting
Plaque Psoriasis
Drug: JNJ-77242113
Drug: Placebo

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...

Enrolling
Atopic Dermatitis
Drug: PF-07264660
Drug: PF-07275315

The study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 2...

Enrolling
Hidradenitis
Chronic Urticaria, Idiopathic
Drug: CSU high dose treatment
Drug: CSU lower dose treatment

The purpose of this study is to explore the effect and Mechanism of Action (MoA) of remibrutinib (LOU064) vs. placebo on clinical outcomes in partici...

Enrolling
Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)
Drug: Remibrutinib
Drug: Placebo

Trial sponsors

Novartis logo
Pfizer logo
Janssen (J&J Innovative Medicine) logo
Boehringer Ingelheim logo
I
Lilly logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems